Tags: ms + rrms.with.MS

Sort by: Date / Title / URL

1. News - Pregnancy and the Postpartum Period Have Protective Effects on Multiple Sclerosis Relapses: Presented at ECTRIMS
   Therefore, these findings demonstrate not only that pregnancy has no adverse effects on the rate of MS relapses, but it also provides further evidence of the beneficial effects both of pregnancy and the postpartum period, over the long term, indicating a
   13-10-2007 to ms, multiple sclerosis, pregnancy, relapsing remitting, rrms, study by admin
2. Momenta Pharmaceuticals Inc (MNTA.O) Full Description | Stocks | Reuters.com
   Momenta's second generic product candidate is M356, a technology-enabled generic version of Copaxone (glatiramer acetate), a complex drug consisting of a mixture of polypeptide chains. Copaxone is indicated for the reduction of the frequency of relapses
   13-08-2007 to copaxone, drug company, drugs, ms, multiple sclerosis, rrms by admin
3. PharmaLive: BioMS Medical's Relapsing-remitting Multiple Sclerosis Trial Receives Positive Review from Data Safety Monitoring Board
   The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 in patients with relapsing-remitting MS.
   25-07-2007 to clinical trial, drug company, drugs, mbp8298, ms, multiple sclerosis, relapsing remitting, rrms by admin
4. Opexa Therapeutics Completes Patient Enrollment in Phase IIb Trial of Tovaxin(TM) for Treatment of Multiple Sclerosis - PipelineReview.com | Business Intelligence Center
   THE WOODLANDS, TX, USA | May 17, 2007 | Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, today announced the completion of patient enrollment in a 150-patient Phase IIb safety and effic
   20-05-2007 to clinical trial, ms, multiple sclerosis, relapsing remitting, rrms, tovaxin, us by admin
5. Welcome to Rebif.com - Multiple Sclerosis (MS) Treatment Information
   13-06-2006 to drug company, drugs, interferon, ms, multiple sclerosis, rebif, relapsing remitting, rrms, treatment by admin
6. Natalizumab Re-approved for Relapsing Multiple Sclerosis
   Natalizumab will be available upon the completion of key activities related to the risk management plan, including FDA review of educational and training materials, internal validation of systems based on final FDA requirements and training of internal pe
   13-06-2006 to drugs, ms, multiple sclerosis, natalizumab, relapsing remitting, rrms, tysabri by admin

First / Previous / Next / Last / Page 1 of 1